MagVenture TMS Therapy

Overview

MagVenture TMS Therapy is MagVenture's entry in the tms devices category, built on Standard TMS + Theta Burst Stimulation (TBS). The platform treats left dorsolateral prefrontal cortex, with 3 minutes (tbs) or 19-37 minutes (standard) and a recommended course of 20-36 sessions over 4-9 weeks. FDA cleared in 2015, it lists in the $75,000-$140,000 range for new units and $35,000-$75,000 on the secondary market.

First TMS platform FDA-cleared for Theta Burst Stimulation (TBS) in 2021. TBS delivers the same clinical effect as standard TMS in a 3-minute session instead of 37 minutes, which dramatically increases patient throughput. The mechanism is what separates MagVenture TMS Therapy from competitors in the same category. Where it fits in your practice depends on patient demographics, treatment volume, and whether you need a flagship platform or a value-tier alternative.

MagVenture TMS Therapy is manufactured by MagVenture (Farum, Denmark, founded 1992). The device benefits from MagVenture's long manufacturer history and presence across 60+ countries. Service support, training availability, and parts access vary by region. Practices considering this device should validate dealer presence and technical support coverage in their area before signing a contract.

Pros & Cons

Clinical Evidence

Multiple RCTs supporting both standard TMS and TBS protocols. Strong European research base, growing US evidence. The published evidence base for MagVenture TMS Therapy reflects how long the platform has been in market and how much the manufacturer has invested in clinical research. Devices with FDA clearance dates before 2018 typically have stronger peer-reviewed datasets than newer entrants. For physicians evaluating this device, the questions worth asking are whether the studies used blinded evaluators, what the sample sizes were, and whether the research was independent or manufacturer-funded.

Compare MagVenture TMS Therapy's evidence base against the category benchmark. In MagVenture TMS Therapy's category, the strongest evidence typically comes from devices that have been on the market for at least five years and have multiple randomized controlled trials with independent funding. Marketing claims from any manufacturer should be cross-checked against PubMed-indexed publications rather than conference posters or white papers. Conference presentations are not equivalent to peer review.

For practices that require strong clinical evidence (academic dermatology, plastic surgery groups with research interests, multi-physician practices that need to defend purchase decisions internally), the evidence profile should be a top-three decision factor. For high-volume cash-pay practices where patient demand drives device selection, brand recognition often matters more than the underlying evidence base. Both approaches are defensible, but they lead to different device selections.

ROI Analysis

Practice ROI for MagVenture TMS Therapy depends on three variables: capital cost, per-session revenue, and treatment volume. At a new unit price of $75,000-$140,000, financed over five years at typical equipment rates, the monthly payment runs roughly 2-2.5% of total cost. Per-session revenue at $250-$500 (insurance reimbursable) means the device needs to fill enough treatment slots monthly to cover the payment, consumables ($1,500-$4,000 (treatment caps)), maintenance ($4,500-$9,000), and operator labor.

For a practice doing 2-3 treatments per day at the midpoint of the per-session range, MagVenture TMS Therapy typically reaches break-even at 12-18 months for the lower end of the new pricing range, or 18-30 months at the high end. Used and refurbished units in the $35,000-$75,000 range can cut payback periods in half. The biggest practice mistake is over-projecting treatment volume. Physicians who run their numbers on 4-6 daily treatments rarely hit those targets in year one.

The realistic question is not whether MagVenture TMS Therapy can pay back. Most devices in this price range do, eventually. The question is whether your practice can fill the schedule. Practices with existing patient flow in Psychiatry, Neurology have the easiest path. Practices building demand from scratch should plan for 6-12 months of marketing investment before the device pays for itself.

Best For

High-volume TMS practices that want to increase daily patient throughput through TBS. Psychiatrists opening new TMS practices who want faster sessions as a competitive differentiator. The fit is strongest for practices that match the device's positioning on price, clinical evidence requirements, and patient throughput expectations. Practices with mismatched economics often regret these purchases within 18 months.

Beyond practice type, MagVenture TMS Therapy fits best when the patient base aligns with the device's strengths. For tms devices platforms, this usually means matching device capability to patient demographics, skin type range, and willingness to pay per-session pricing. Practices in markets where patients price-shop heavily need to factor that into device selection. Practices in concierge or luxury markets can charge premium pricing that justifies premium platforms.

Buying Guide

New MagVenture TMS Therapy units sell for $75,000-$140,000 from MagVenture or authorized dealers. Refurbished and used units sell for $35,000-$75,000 on the secondary market. The decision between new and used comes down to warranty coverage, software version, included applicators, and consumable allowances. New units typically include a 12-24 month warranty, current software, all applicators, and a starter consumable package. Used units usually carry no warranty, may have outdated software, and require separate consumable purchases.

What to negotiate: applicator quantity (always ask for additional applicators thrown in), consumable starter packs, training and certification fees, extended warranty coverage, marketing materials, and clinical training for additional providers. MagVenture sales reps typically have 10-15% list price flexibility and far more on bundled deals. End-of-quarter and end-of-year are the strongest negotiation windows. Trade-in programs for older devices can reduce net cost by another 10-20%.

What to watch for: software lock-out fees on used units (some manufacturers disable software on resold devices), per-pulse or per-treatment licensing fees that show up after purchase, consumable price increases over the device life, and service contract terms. Always require a written quote that breaks out hardware, applicators, training, first-year service, and consumables separately. Bundled quotes hide the line items where margins live.

MagVenture TMS Machine Cost: Pricing Guide

MagVenture TMS machine cost runs $75,000-$140,000 for a new system, while used units run $35,000-$75,000. Device Pulse reports per-session pricing of $250-$500, which is insurance reimbursable.

That range gives a practice or hospital a starting point. It does not settle the purchase decision. The machine price is only one cost line, and MagVenture's case rests heavily on the economics of Theta Burst Stimulation.

MagVenture TMS Therapy is built on Standard TMS + Theta Burst Stimulation (TBS). It treats the left dorsolateral prefrontal cortex and is manufactured by MagVenture in Farum, Denmark.

MagVenture TMS Machine Cost in 2026

The purchase price is the first line item buyers ask about because it is the check they have to write. New MagVenture systems run $75,000-$140,000, and used units run $35,000-$75,000, according to Device Pulse's MagVenture review.

Per-session pricing runs $250-$500 and is insurance reimbursable, according to Device Pulse's MagVenture review. A device can look expensive on the purchase order and still make sense inside a reimbursable clinical program. The opposite is also true. A lower acquisition price does little good if the program cannot keep a schedule full or service the device quickly.

The sensible way to read the range is as an opening budget, not a final total. A new system generally offers the cleanest path for warranty, installation, training, and vendor support. A used system can lower the upfront cost, but the buyer should know its service history, coil condition, software status, available warranty, and local technical support before treating the discount as savings.

The MagVenture cost breakdown is useful when your finance team needs the device line separated from the recurring operating costs. That conversation tends to get muddled when someone treats a capital purchase and a clinical program as the same thing.

MagVenture was founded in 1992 in Farum, Denmark, and operates across 60+ countries, according to Device Pulse. Geographic reach is not a substitute for local support. A hospital system should validate dealer presence, installation capacity, response expectations, and technical support coverage in its own market before signing a contract.

The BrainsWay comparison ranges come from Device Pulse's cost guide, which puts a new Deep TMS system at $100,000-$200,000 and used units at $50,000-$120,000. The table is a purchasing aid, not a clinical verdict. Price can narrow the field. It should not choose the platform by itself.

What the MagVenture Price Includes

MagVenture TMS Therapy is a platform, not a single undifferentiated machine. The clinical configuration matters because Standard TMS and TBS create different scheduling possibilities. Buyers should ask the seller to spell out the exact hardware, coils, software, training, installation, warranty terms, service coverage, and any site-readiness requirements included in the quoted price.

That level of detail protects both sides. Practices often compare a low headline quote with a more complete quote and assume the difference is vendor margin. Sometimes it is. Sometimes one quote includes the practical work needed to get patients treated while the other leaves the buyer holding a list of follow-on expenses.

The platform was FDA cleared in 2015, with a recommended course of 20-36 sessions over 4-9 weeks, according to Device Pulse. MagVenture was also the first TMS platform FDA-cleared for Theta Burst Stimulation in 2021.

For psychiatrists, that distinction affects how a treatment plan fits into the day. For practice owners, it affects whether the service line fits into the existing clinic. For hospital buyers, it affects staffing, room demand, and the value of keeping a device available rather than idle.

The TMS and neuromodulation category provides the broader market context. It helps to compare the clinical and operating model around a platform, not only the sticker price.

Theta Burst Stimulation and Patient Throughput

TBS is MagVenture's strongest economic argument. TBS delivers the same clinical effect as standard TMS in a 3-minute session instead of 37 minutes, according to Device Pulse.

The difference changes the shape of a day. A standard protocol can dominate a treatment room and tie up staff attention for long stretches. A shorter TBS session gives the clinic more room to absorb cancellations, fit in evaluations, and keep its schedule from turning into a mess after one late patient.

That does not mean every patient will receive the same protocol, or that every organization can instantly turn shorter sessions into higher utilization. Clinical judgment still governs treatment. Staffing, referral flow, payer rules, room availability, and patient adherence determine whether theoretical throughput becomes booked care.

But the underlying advantage is straightforward. When treatment time falls from 37 minutes to 3 minutes, the machine has more potential capacity. A program that cannot access that capacity because it has weak referrals or poor scheduling will not capture much value. A program with demand and disciplined operations has a different equation.

This is where hospital procurement can get too focused on acquisition cost. A system that costs less upfront but consumes far more room time can become the more expensive choice once the program is established. The purchase committee should ask clinical leadership how the intended protocol mix changes scheduling, staffing, and referral capacity.

TBS also affects patient experience. Repeated appointments are easier to accommodate when the appointment itself does not consume most of an hour. That does not erase the commitment involved in a full course of care. It does reduce one source of friction for patients trying to fit treatment into work, family, and transportation constraints.

MagVenture wins this comparison when the organization has enough patient demand to use the shorter appointment window. A low-volume site may value other factors more heavily. A busy outpatient program or hospital service line has more to gain from a device that gives the schedule some breathing room.

Annual Operating Costs

The device purchase gets attention because it is visible. Annual operating costs determine whether the program stays financially comfortable after the launch period.

Treatment cap consumables run $1,500-$4,000 per year, while maintenance runs $4,500-$9,000 per year, according to Device Pulse's MagVenture review. Those are recurring costs, and they belong in the business case from the start.

Consumables are easy to minimize in a presentation because they are smaller than the machine price. That is a mistake. They are part of the actual cost of delivering treatment, and the range should be reconciled with the expected protocol mix, anticipated patient volume, and the organization's procurement process.

Maintenance deserves more scrutiny. Ask what is covered under warranty, what begins after warranty, what turnaround expectations apply, whether loaner equipment is available, and whether local technicians can respond without a long delay. A device out of service creates a repair bill, disrupts patient care, and turns a planned schedule into a triage exercise.

The contract should also make support coverage legible. "Service available" is vague. Buyers should understand who receives the call, who performs the work, what parts are included, and what happens when the equipment needs attention at an inconvenient moment. Equipment always chooses an inconvenient moment.

For hospital buyers, ownership may also touch facilities, information security, credentialing, room allocation, and purchasing workflows. Those items vary by organization, so they should be surfaced in the internal approval process rather than buried in a generic cost model.

MagVenture vs Other TMS Platforms on Cost

MagVenture's new-system range sits below the $100,000-$200,000 range reported for a new BrainsWay Deep TMS system, while used BrainsWay units run $50,000-$120,000, according to Device Pulse's BrainsWay cost guide.

That comparison gives MagVenture an upfront cost advantage on the published ranges. It does not establish that MagVenture is the right clinical or commercial fit for every program. Device selection depends on the treatments your clinicians plan to offer, the patient population you expect to serve, local referral patterns, support coverage, and the economics of the protocols you will use.

NeuroStar belongs in the same purchasing conversation for many hospital buyers, particularly where established local relationships or clinical familiarity shape the evaluation. The NeuroStar vs BrainsWay Deep TMS comparison can help frame that side of the market. MagVenture should be evaluated alongside both platforms using the same decision criteria, rather than comparing each quote in isolation.

A strong comparison process asks each vendor for a quote with matching assumptions. Include the clinical configuration, installation, training, service terms, consumables, warranty, and any recurring fees. If the assumptions differ, the quoted price will differ for reasons that have little to do with the underlying value of the platform.

MagVenture's TBS capability should be placed beside the cost comparison, not left in a clinical appendix. A buyer deciding between platforms is deciding how a treatment service operates day to day. The financial model should reflect that reality.

BrainsWay may be more expensive on the published purchase ranges. MagVenture may offer stronger throughput economics where TBS fits the program. NeuroStar may carry advantages specific to a buyer's local market or clinical preference. The winner is the platform whose clinical model and operating model match the program you are building.

Pros and Cons for Buyers

MagVenture's main advantage is the combination of Standard TMS and Theta Burst Stimulation. The published price range is lower than BrainsWay's published range, and the shorter TBS session can materially change how a busy clinic uses its rooms and staff.

The tradeoff is that machine price alone does not explain total ownership cost. Buyers still need a clear picture of annual treatment cap spending, maintenance, installation, warranty, local service, and the operational work needed to fill the schedule.

Used equipment may appeal to a practice looking to control its initial investment. That path requires more diligence, not less. Confirm the unit's condition, support eligibility, remaining useful life, and whether the seller can provide documentation that will satisfy your clinicians, finance team, and compliance process.

New equipment is easier to defend when the program needs predictable support and a clean implementation path. The premium can be worth it when downtime, training, and vendor accountability carry more weight than the initial purchase price.

The Buyer Kit Questions to Ask Before Signing

A buyer kit should force the vendor conversation beyond the device brochure. Request the full quote, service agreement, warranty language, consumables schedule, training plan, installation requirements, and a written explanation of local support coverage.

Ask the clinical team which protocols it expects to use and how TBS fits the intended care model. Ask operations how the program will schedule patients, staff treatment rooms, and handle missed appointments. Ask finance how it will treat the capital purchase and recurring expenses.

Then compare each vendor against the same assumptions. That is how a hospital avoids selecting a platform because one proposal made the first line look cheaper.

MagVenture is a credible option for buyers who value TBS throughput and want a published purchase range below BrainsWay's. The real question is whether your local support, clinical plan, and referral demand are strong enough to turn that advantage into a durable TMS program.

Alternatives to review

Use these profiles to build a short list. An alternative listing is not a claim of equivalence or superiority.